[Study of the antitumor activity of carminomycin in malignant tumors in children (a preliminary report)].
Side reactions and therapeutic effect of carminomycin were studied in 21 children with various malignant tumors. Carminomycin was administered intravenously in doses of 0.15-0.2 mg/kg twice a week for 2-3 weeks. The treatment courses were repeated in a month. The drug was better tolerated by children than by adults. After the treatment course leucopenia may develop. When used alone or in combination with vincristin or cyclophosphan carminomycin proved to be effective in treatment of sarcoma of the soft tissues (liposarcoma, synovial sarcoma), chondrosarcoma and reticulosarcoma.
D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002360:Carubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D009031:Moscow; D009369:Neoplasms / Q000188:drug therapy*; D012075:Remission, Spontaneous; D012509:Sarcoma / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D002360:Carubicin
Izuchenie protivoopukholevoĭ aktivnosti karminomitsina pri zlokachestvennykh opukholiakh u deteĭ (predvaritel'noe soobshchenie)